Copaxone

Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade

Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade

Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant

Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade

Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant

Teva's Cost-Cutting Plan Nets A Mizuho Upgrade

For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst

Teva's Cost-Cutting Plan Nets A Mizuho Upgrade

For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst

Analyst Eats 'Some Humble Pie,' Says Teva Needs To Deliver On Greater Visibility In Coming Months

Momenta Pharma Could Face Pressure Following Approval Of Mylan's Generic Copaxone

Copaxone Recent News

Mylan And Teva And Copaxone, Explained

Mylan's Generic Copaxone Arrives, Teva Sales To Take A Hit

Why Is Teva Falling? Competition

What Approval For Generic Copaxone Means For Mylan

Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

The Prescription For Generic Drugs ETF

Teva Downgraded As Analyst Casts Doubt On Turnaround Story

Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date

Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'

Citi Weighs In On The 'Turmoil At Teva'

A District Court's Ruling Against Teva Pharma Opens The Door For Generics

What The Copaxone Court Ruling Means For Teva Pharmaceuticals

Orphan Drugs Among 2015's Top 10 Best-Selling Medications

Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision

Jefferies Warns Of 'Too Many Headwinds' For Teva

Teva Pharmaceuticals Could Be Poised For A Turnaround

Synthetic Biologics Crashes Following Disappointing Phase 2 Results

Momenta Pharmaceuticals Spikes Up Following FDA News On Copaxone

Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks

Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition

Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss

Market Wrap For May 1: Markets Mixed To Start The New Month